Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8294114 | 0.86 | TAAR1 (0.61) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL10852152 | 0.84 | SLC6A4 (0.61) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL29661816 | 0.84 | SLC6A4 (0.61) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL2485767 | 0.83 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL29664514 | 0.83 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL28123545 | 0.83 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL30904507 | 0.83 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL9361151 | 0.83 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL15162053 | 0.83 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL393456 | 0.83 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7901949-B2 | Assay | ALERE SWITZERLAND GMBH (CH) | 2011-03-08 | — | — | US | claimed |
| EP-4351568-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | Mindset Pharma Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-20210046014-A1 | PHARMACEUTICAL ABUSE DETERRENT COMPOSITION CONSTRUCTED IN MORE THAN ONE STRENGTHS | Patel, Jayendrakumar Dasharathlal (IN) | 2021-02-18 | — | — | US | disclosed |
| US-20200368169-A1 | ABUSE-DETERRENT COMPOSITIONS | PATHEON SOFTGELS INC (US) | 2020-11-26 | — | — | US | disclosed |
| US-10772841-B2 | Opioid abuse-deterrent controlled release formulations | PATHEON SOFTGELS INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10772842-B2 | Abuse-deterrent opioids | PATHEON SOFTGELS INC. (US) | 2020-09-15 | — | — | US | disclosed |
| CN-105938135-B | Analysis device comprising a bubble formation mechanism | SPD瑞士精确诊断有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10478429-B2 | Abuse deterrent dosage forms | Patheon Softgels, Inc. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10335405-B1 | Non-burst releasing pharmaceutical composition | Patheon Softgels, Inc. (US) | 2019-07-02 | — | — | US | disclosed |
| WO-2019064082-A2 | PHARMACEUTICAL ABUSE DETERRENT COMPOSITION CONSTRUCTED IN MORE THAN ONE STRENGTHS | PATEL JAYENDRAKUMAR DASHARATHLAL (IN) | 2019-04-04 | — | — | WO | disclosed |
| EP-1167976-A2 | Immunoassay for the detection of amphetamines and derivatives thereof | BOEHRINGER MANNHEIM GMBH (DE) | 2002-01-02 | — | — | EP | disclosed |
| US-4751246-A | ALPHA(AMINOALKYL)-4-HYDROXY-3-(ALKYLSULFINYL) BENZENEMETHANOL AND 2-(4-HYDROXY-3-(ALKYLSULFINYL) PHENYL)ETHYLAMINE-HYPOTENSIVE AGENTS | STERLING DRUG INC. (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| EP-0168543-A1 | (aralkylamino-2-or-propoxy)heterocyclic compounds | MERCK & CO. INC. (US) | 1986-01-22 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| US-4472427-A | (Aralkylamino-2-OR-propoxy)heterocyclic compounds | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
| US-4452816-A | HYPOTENSIVE AND ANTIARRHYTHMIA AGENTS | STERLING DRUG INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4374149-A | HYPOTENSIVE AGENT AND VASODILATOR | STERLING DRUG INC. (US) | 1983-02-15 | — | — | US | disclosed |
| US-4221808-A | Novel antihypertensive agent | RICHARDSON-MERRELL INC. (US) | 1980-09-09 | — | — | US | disclosed |